Market Place
Sourcing Support
Krystal Bio To Present At TD Cowen Health Care Conference
24 Feb 2026 //
GLOBENEWSWIRE
Krystal Biotech To Release Q3 2025 Financial Results On Nov 3
21 Oct 2025 //
GLOBENEWSWIRE
Jeune Aesthetics Names Nishant As Chief Financial Officer
14 Jan 2025 //
GLOBENEWSWIRE
Krystal Doses First KB707 Lung Cancer Patient
22 Apr 2024 //
GLOBENEWSWIRE
Krystal Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707
13 Feb 2024 //
GLOBENEWSWIRE
Krystal Announces Publication on the Application of B-VEC
08 Feb 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Krystal to Present at Association for Research in Vision & Ophthalmology Meeting
13 Apr 2023 //
GLOBENEWSWIRE
New England Journal of Medicine Publishes Phase 3 Data on B-VEC
14 Dec 2022 //
GLOBENEWSWIRE
Suma Krishnan co-founded a company to develop treatment for ‘the worst disease’
08 Dec 2022 //
ENDPTS
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic
05 Dec 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
01 Dec 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
23 Nov 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces 3Q 2022 Financial Results and Operational Highlights
07 Nov 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
29 Sep 2022 //
GLOBENEWSWIRE
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee
21 Sep 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at H.C. Wainwright 24th Annual GHC
08 Sep 2022 //
GLOBENEWSWIRE
FDA Accepts Krystal Biotech’s BLA for Dystrophic Epidermolysis Bullosa
18 Aug 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
FDA Accepts Krystal Biotech`s KB407 IND Application for Cystic Fibrosis
01 Aug 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for CF
01 Aug 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
06 Jul 2022 //
GLOBENEWSWIRE
Krystal Biotech Submits BLA to U.S. FDA Seeking Approval of B-VEC for DEB
22 Jun 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at Goldman Sachs Healthcare Conference
07 Jun 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 PIII Study
19 May 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
09 May 2022 //
NASDAQ
Krystal Biotech to Participate in Bank of America Merrill Lynch Conference
03 May 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
11 Apr 2022 //
GLOBENEWSWIRE
Krystal Biotech Announces Publication of Phase 1 and 2 Trial of B-VEC Data
28 Mar 2022 //
GLOBENEWSWIRE
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 AAD
26 Mar 2022 //
GLOBENEWSWIRE
Krystal Biotech to Participate in H.C. Wainwright, Guggenheim Conferences
24 Mar 2022 //
GLOBENEWSWIRE
Krystal Biotech to Present at 2022 American Academy of Dermatology
18 Mar 2022 //
GLOBENEWSWIRE
Krystal Biotech says Settlement with PeriphaGen, Inc.
15 Mar 2022 //
GLOBENEWSWIRE
Krystal Biotech Reports Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
24 Feb 2022 //
GLOBENEWSWIRE
Krystal’s dystrophic EB gene therapy trial meets primary goal
30 Nov 2021 //
CLINICALTRIALSARENA
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
29 Nov 2021 //
GLOBENEWSWIRE
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study
26 Oct 2021 //
GLOBENEWSWIRE
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407
19 Oct 2021 //
GLOBENEWSWIRE
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408
14 Oct 2021 //
GLOBENEWSWIRE
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge
12 Oct 2021 //
GLOBENEWSWIRE
Krystal Biotech to Present at the Chardan 5th Genetic Medicines Conference
01 Oct 2021 //
GLOBENEWSWIRE
Krystal Biotech Receives Approval Ethics Australia for Ph1 Trial of KB407
29 Sep 2021 //
GLOBENEWSWIRE
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
15 Sep 2021 //
GLOBENEWSWIRE
Krystal Announces Virtual Presentation of Data its Vector-Encoded-Antibody
27 Apr 2021 //
GLOBENEWSWIRE
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
26 Apr 2021 //
BIOSPACE
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
19 Apr 2021 //
GLOBENEWSWIRE
Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3
30 Mar 2021 //
BIOSPACE
Krystal Biotech Provides Update on Operational Progress and Reports Fourth
01 Mar 2021 //
GLOBENEWSWIRE
Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock
02 Feb 2021 //
BUSINESSWIRE
Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering
02 Feb 2021 //
BIOSPACE
Krystal Biotech to Present at the Evercore ISI HealthCONx Conference
24 Nov 2020 //
BUSINESSWIRE
Krystal Biotech to Present Pre-clinical Data Highlighting KB301
08 Oct 2020 //
PRESSRELEASE
Krystal Biotech Announces Initiation of Ph1 Study Evaluating KB301
25 Aug 2020 //
GLOBENEWSWIRE
Krystal Biotech’s KB407 Granted Orphan Drug by the FDA to Treat Patients
17 Aug 2020 //
GLOBENEWSWIRE
Pivotal Ph3 Trial Testing Topical Gene Therapy B-VEC Now DEB Patients
05 Aug 2020 //
EPIDERMOLYSIS
Krystal Biotech initiates phase 3 GEM-3 study of beremagene geperpavec
29 Jul 2020 //
PHARMABIZ
Krystal Biotech Announces Initiation of Pivotal Ph3 Study Beremagene Geperpavec
28 Jul 2020 //
GLOBENEWSWIRE
Krystal Biotech to present positive interim results from ph 1/2 trial of KB105
18 May 2020 //
PHARMABIZ
